Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus CHOP versus rituximab plus CHOP in previously untreated CD20-positive diffuse large B-cell lymphoma
jRCT2080221618Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Oct 2011; status: completed.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2080221618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221618.